Inhibikase Financial Statements From 2010 to 2024
| IKT Stock | USD 1.86 0.02 1.09% |
Gross Profit -8.3 M | Market Capitalization 14.6 M | Enterprise Value Revenue 2.748 | Revenue 196 K | Earnings Share (3.41) |
Inhibikase Therapeutics Total Revenue |
|
Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.9 K, Net Interest Income of 935.8 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 24.7, Dividend Yield of 0.0 or PTB Ratio of 0.65. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
Inhibikase | Select Account or Indicator |
Inhibikase Therapeutics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibikase Therapeutics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibikase Therapeutics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibikase Therapeutics Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibikase Fundamental Market Drivers
| Cash And Short Term Investments | 13.3 M |
Inhibikase Upcoming Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Inhibikase Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Inhibikase Therapeutics income statement, its balance sheet, and the statement of cash flows. Inhibikase Therapeutics investors use historical funamental indicators, such as Inhibikase Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Inhibikase Therapeutics investors may use each financial statement separately, they are all related. The changes in Inhibikase Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inhibikase Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inhibikase Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inhibikase Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.7 M | 1.5 M | |
| Total Revenue | 260.5 K | 247.5 K | |
| Cost Of Revenue | 177.4 K | 168.5 K | |
| Stock Based Compensation To Revenue | 1.92 | 1.32 | |
| Sales General And Administrative To Revenue | 0.56 | 0.50 | |
| Research And Ddevelopement To Revenue | 52.28 | 54.89 | |
| Capex To Revenue | (0.05) | (0.06) | |
| Revenue Per Share | 0.05 | 0.05 | |
| Ebit Per Revenue | (77.12) | (80.98) |
Pair Trading with Inhibikase Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inhibikase Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Inhibikase Stock
| 0.61 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.58 | ELDN | Eledon Pharmaceuticals | PairCorr |
| 0.57 | DSGN | Design Therapeutics | PairCorr |
| 0.51 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Inhibikase Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inhibikase Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inhibikase Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inhibikase Therapeutics to buy it.
The correlation of Inhibikase Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inhibikase Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inhibikase Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inhibikase Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.